Investigations of line scanning proton therapy with dynamic multi-leaf collimator.

PURPOSE: Scanning proton therapy has dosimetric advantage over passive treatment, but has a large penumbra in low-energy region. This study investigates the penumbra reduction when multi-leaf collimators (MLCs) are used for line scanning proton beams and secondary neutron production from MLCs. METHODS: Scanning beam plans with and without MLC shaping were devised. Line scanning proton plan of 36 energy layers between 71.2 and 155.2 MeV was generated. The MLCs were shaped according to the cross-sectional target shape for each energy layer. The two-dimensional doses were measured through an ion-chamber array, depending on the presence of MLC field, and Monte Carlo (MC) simulations were performed. The plan, measurement, and MC data, with and without MLC, were compared at each depth. The secondary neutron dose was simulated with MC. Ambient neutron dose equivalents were computed for the line scanning with 10 × 10 × 5 cm3 volume and maximum proton energy of 150 MeV, with and without MLCs, at lateral distances of 25-200 cm from the isocenter. The neutron dose for a wobbling plan with 10 × 10 × 5 cm3 volume was also evaluated. RESULTS: The lateral penumbra width using MLC was reduced by 23.2% on average, up to a maximum of 32.2%, over the four depths evaluated. The ambient neutron dose equivalent was 18.52% of that of the wobbling beam but was 353.1% larger than the scanning open field. CONCLUSIONS: MLC field shaping with line scanning reduced the lateral penumbra and should be effective in sparing normal tissue. However, it is important to investigate the increase in neutron dose.

Proton range verification in inhomogeneous tissue: Treatment planning system vs. measurement vs. Monte Carlo simulation.

In particle radiotherapy, range uncertainty is an important issue that needs to be overcome. Because high-dose conformality can be achieved using a particle beam, a small uncertainty can affect tumor control or cause normal-tissue complications. From this perspective, the treatment planning system (TPS) must be accurate. However, there is a well-known inaccuracy regarding dose computation in heterogeneous media. This means that verifying the uncertainty level is one of the prerequisites for TPS commissioning. We evaluated the range accuracy of the dose computation algorithm implemented in a commercial TPS, and Monte Carlo (MC) simulation against measurement using a CT calibration phantom. A treatment plan was produced for eight different materials plugged into a phantom, and two-dimensional doses were measured using a chamber array. The measurement setup and beam delivery were simulated by MC code. For an infinite solid water phantom, the gamma passing rate between the measurement and TPS was 97.7%, and that between the measurement and MC was 96.5%. However, gamma passing rates between the measurement and TPS were 49.4% for the lung and 67.8% for bone, and between the measurement and MC were 85.6% for the lung and 100.0% for bone tissue. For adipose, breast, brain, liver, and bone mineral, the gamma passing rates computed by TPS were 91.7%, 90.6%, 81.7%, 85.6%, and 85.6%, respectively. The gamma passing rates for MC for adipose, breast, brain, liver, and bone mineral were 100.0%, 97.2%, 95.0%, 98.9%, and 97.8%, respectively. In conclusion, the described procedure successfully evaluated the allowable range uncertainty for TPS commissioning. The TPS dose calculation is inefficient in heterogeneous media with large differences in density, such as lung or bone tissue. Therefore, the limitations of TPS in heterogeneous media should be understood and applied in clinical practice.

Cumulative dose on fractional delivery of tomotherapy to periodically moving organ: a phantom QA suggestion.

This study was conducted to evaluate the cumulative dosimetric error that occurs in both target and surrounding normal tissues when treating a moving target in multifractional treatment with tomotherapy. An experiment was devised to measure cumulative error in multifractional treatments delivered to a horseshoe-shaped clinical target volume (CTV) surrounding a cylinder shape of organ at risk (OAR). Treatments differed in jaw size (1.05 vs 2.5cm), pitch (0.287 vs 0.660), and modulation factor (1.5 vs 2.5), and tumor motion characteristics differing in amplitude (1 to 3cm), period (3 to 5 second), and regularity (sinusoidal vs irregular) were tested. Treatment plans were delivered to a moving phantom up to 5-times exposure. Dose distribution on central coronal plane from 1 to 5 times exposure was measured with GAFCHROMIC EBT film. Dose differences occurring across 1 to 5 times exposure of treatment and between treatment plans were evaluated by analyzing measurements of gamma index, gamma index histogram, histogram changes, and dose at the center of the OAR. The experiment showed dose distortion due to organ motion increased between multiexposure 1 to 3 times but plateaued and remained constant after 3-times exposure. In addition, although larger motion amplitude and a longer period of motion both increased dosimetric error, the dose at the OAR was more significantly affected by motion amplitude rather than motion period. Irregularity of motion did not contribute significantly to dosimetric error when compared with other motion parameters. Restriction of organ motion to have small amplitude and short motion period together with larger jaw size and small modulation factor (with small pitch) is effective in reducing dosimetric error. Pretreatment measurements for 3-times exposure of treatment to a moving phantom with patient-specific tumor motion would provide a good estimation of the delivered dose distribution.

Development of a video-guided real-time patient motion monitoring system.

PURPOSE: The authors developed a video image-guided real-time patient motion monitoring (VGRPM) system using PC-cams, and its clinical utility was evaluated using a motion phantom. METHODS: The VGRPM system has three components: (1) an image acquisition device consisting of two PC-cams, (2) a main control computer with a radiation signal controller and warning system, and (3) patient motion analysis software developed in-house. The intelligent patient motion monitoring system was designed for synchronization with a beam on/off trigger signal in order to limit operation to during treatment time only and to enable system automation. During each treatment session, an initial image of the patient is acquired as soon as radiation starts and is compared with subsequent live images, which can be acquired at up to 30 fps by the real-time frame difference-based analysis software. When the error range exceeds the set criteria (δ(movement)) due to patient movement, a warning message is generated in the form of light and sound. The described procedure repeats automatically for each patient. A motion phantom, which operates by moving a distance of 0.1, 0.2, 0.3, 0.5, and 1.0 cm for 1 and 2 s, respectively, was used to evaluate the system performance. The authors measured optimal δ(movement) for clinical use, the minimum distance that can be detected with this system, and the response time of the whole system using a video analysis technique. The stability of the system in a linear accelerator unit was evaluated for a period of 6 months. RESULTS: As a result of the moving phantom test, the δ(movement) for detection of all simulated phantom motion except the 0.1 cm movement was determined to be 0.2% of total number of pixels in the initial image. The system can detect phantom motion as small as 0.2 cm. The measured response time from the detection of phantom movement to generation of the warning signal was 0.1 s. No significant functional disorder of the system was observed during the testing period. CONCLUSIONS: The VGRPM system has a convenient design, which synchronizes initiation of the analysis with a beam on/off signal from the treatment machine and may contribute to a reduction in treatment error due to patient motion and increase the accuracy of treatment dose delivery.

Analysis of changes in dose distribution due to respiration during IMRT.

PURPOSE: Intensity modulated radiation therapy (IMRT) is a high precision therapy technique that can achieve a conformal dose distribution on a given target. However, organ motion induced by respiration can result in significant dosimetric error. Therefore, this study explores the dosimetric error that result from various patterns of respiration. MATERIALS AND METHODS: Experiments were designed to deliver a treatment plan made for a real patient to an in-house developed motion phantom. The motion pattern; the amplitude and period as well as inhale-exhale period, could be controlled by in-house developed software. Dose distribution was measured using EDR2 film and analysis was performed by RIT113 software. Three respiratory patterns were generated for the purpose of this study; first the 'even inhale-exhale pattern', second the slightly long exhale pattern (0.35 seconds longer than inhale period) named 'general signal pattern', and third a 'long exhale pattern' (0.7 seconds longer than inhale period). One dimensional dose profile comparisons and gamma index analysis on 2 dimensions were performed RESULTS: In one-dimensional dose profile comparisons, 5% in the target and 30% dose difference at the boundary were observed in the long exhale pattern. The center of high dose region in the profile was shifted 1 mm to inhale (caudal) direction for the 'even inhale-exhale pattern', 2 mm and 5 mm shifts to exhale (cranial) direction were observed for 'slightly long exhale pattern' and 'long exhale pattern', respectively. The areas of gamma index >1 were 11.88%, 15.11%, and 24.33% for 'even inhale-exhale pattern', 'general pattern', and 'long exhale pattern', respectively. The long exhale pattern showed largest errors. CONCLUSION: To reduce the dosimetric error due to respiratory motions, controlling patient's breathing to be closer to even inhaleexhale period is helpful with minimizing the motion amplitude.

Variation of small bowel sparing with small bowel displacement system according to the physiological status of the bladder during radiotherapy for cervical cancer.

OBJECTIVE: To evaluate the reproducibility of small bowel displacement system (SBDS) volumetrically using weekly CT throughout a regimen of radiotherapy for the treatment of cervical cancer. METHODS: From October 2004 to January 2005, 10 consecutive patients who received pelvic radiation therapy for uterine cervical carcinoma with the SBDS were included in this study. With the patient laid prone on the conventional simulator table, the Styrofoam compression device is placed under the lower abdomen of the patient. Next, CT scan images, first two sets of without and with the SBDS, followed by with SBDS once a week for 3 weeks consecutively after the beginning of radiotherapy, were taken. Radiation planning was performed using standard pelvic box fields in 3-dimensional radiation treatment planning system. In each CT sets, we measured the identified organ volumes and the volume of small bowel irradiated in treatment portals. We used the regression analysis to know the correlation of the volume of small bowel irradiated according to the volume variation of bladder during radiotherapy. RESULTS: The mean small bowel volume with SBDS of 10 patients during radiotherapy was reduced by 60.5% (from 32.5% to 78.2%), comparing to the small bowel volume without SBDS. The variation of small bowel volume reduction in each patient was ranged from 7.3% to 38.5% (mean: 20.5%). In spite of using the SBDS, the volume reduction of small bowel irradiated was affected significantly by the volume of bladder during radiotherapy. The variation of small bowel irradiated for five patients who had more than 10% small bowel volume variation was significantly correlated with the volume of bladder, but not for five patients less than 10% small bowel volume variation. CONCLUSION: We confirm that in spite of the variation of bladder volume during radiotherapy, the SBDS is an effective method that can be used to displace the small bowel continuously away from the irradiated field for cervical cancer.